17,261 trials
Actinic Keratosis
Primary: Part 1: To Identify the Maximum Tolerated Dose (MTD) Levels After Once Daily Treatment for 2 or 3 Days — 0; 0; 0; 1 Participants
Dry Eye Disease (DED)
Primary: Corneal Fluorescein Staining (CFS) Total (National Eye Institute (NEI) Grading) — -1.78; -2.11; -0.93 score on a scale
Graft-versus-host-disease · GVHD
Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Cocaine Use Disorder
Primary: The Number of Participants Who Achieved Abstinence From Cocaine During the Last Three Weeks of the Trial — 2; 2 participants — p==0.97
Scleroderma, Systemic
Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) — 8; 3; 24; 1 Participants
Plasmodium Falciparum
Primary: Part A Dose-Escalation: Number of Participants Who Experienced Any Serious Adverse Events Related To Vaccine Administration — 0; 0 Participants
Systemic Sclerosis, Scleroderma
Primary: Change From Baseline in Modified Rodnan Skin Score (MRSS) at Each Time Point of Analysis — 25.7; 6.58; 5.97; 8.34 units on a scale
COVID-19
Primary: Participants With a Disease Control Status Defined as no Disease Progression to Severe. — 30; 26 Participants
Vitiligo
Primary: Change in Pigmentation (Total and Individual Body Parts) Using the Vitiligo Area Scoring Index (VASI) — 0.00; 0.00; 0.00; 0.00 Change in VASI score from baseline
Multiple Myeloma
Primary: Evaluation of the Response Rate of Ixazomib With Metronomic Cyclophosphamide and Dexamethasone for First-line Treatment of Multiple Myeloma. — 12 Participants
Venous Thromboembolism · Haemorrhage
Primary: Incidence of Symptomatic Venous Thromboembolism Plus Asymptomatic Proximal Vein Thrombosis and All-cause Mortality — 1; 7 participants — p=0.03
Kidney Failure, Chronic
Primary: Number of Patients With Crossmatch Conversion (Positive to Negative) — 17; 2 Patients
Acute Respiratory Distress Syndrome · Cytokine Release Syndrome · Covid19
Primary: One-month Mortality Rate Between the Two Arms — 0; 3 participants
Septic Shock
Primary: Time to Resolution of Shock — 89; 84 Hours